23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › MOONLAKE IMMUNOTHERAPEUTICS › 2025-2026

MOONLAKE IMMUNOTHERAPEUTICS 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and MOONLAKE IMMUNOTHERAPEUTICS’s Form 8-K, filed June 9, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Reported items
  • 123Asset managers, any item
  • 317Fund votes
  • June 4, 2026Meeting date

Results at a glance

Meeting of June 4, 2026: 3 items on MOONLAKE IMMUNOTHERAPEUTICS’s Form 8-K, filed June 9, 2026: 3 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore MOONLAKE IMMUNOTHERAPEUTICS in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by MOONLAKE IMMUNOTHERAPEUTICS

These tallies are MOONLAKE IMMUNOTHERAPEUTICS’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

MOONLAKE IMMUNOTHERAPEUTICS — official shareholder meeting results, meeting held June 4, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
2. Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor 61,831,46317,52223,521 --0 99.9%Passed (calculated)—
3. Advisory Vote on Executive Compensation 50,365,168731,15815,038 --10,761,142 99%Passed (calculated)—
4. Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan 50,599,032498,18614,146 --10,761,142 99.0%Passed (calculated)—

Source: MOONLAKE IMMUNOTHERAPEUTICS, Form 8-K, filed with the SEC on June 9, 2026 — read the filing on EDGAR.

How asset managers voted at the MOONLAKE IMMUNOTHERAPEUTICS 2025-2026 meeting

123 asset managers disclosed a vote on at least one MOONLAKE IMMUNOTHERAPEUTICS item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of MOONLAKE IMMUNOTHERAPEUTICS’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Election of the Class I director nominee to serve until the 2029 Annual General Meeting of Shareholders and…: Spike Loy

No official matchDIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

96% of fund votes cast · no official result

FOR
Details: description as filed, votes by 18 asset managers

Description as filed by funds: Election of the Class I director nominee to serve until the 2029 Annual General Meeting of Shareholders and until his successor is duly elected and qualified: Spike Loy

The 18 asset managers below reported 2,250,906 for, 90,766 withheld, 2 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 2,250,906ABSTAIN: 2WITHHOLD: 90,766
Largest asset managers voting on “Election of the Class I director nominee to serve until the 2029 Annual General Meeting of Shareholders and un” at MOONLAKE IMMUNOTHERAPEUTICS, 2025-2026
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price1,222,1730 00For
BlackRock286,4160 00For
Fidelity231,8400 00For
Jackson National111,7540 00For
Vanguard94,9800 2251For
Invesco94,2340 00For
Delaware/Macquarie00 080,000Withhold
Victory Capital64,3170 00For
ALPS ETF Trust58,3950 00For
Advisor Managed Portfolios24,4190 00For
John Hancock22,5850 00For
ETFis Series Trust I17,5620 00For
Equitable17,1510 00For
CLEARWATER INVESTMENT TRUST00 010,515Withhold
Blackstone Alternative Investment Funds4,0000 00For
Harbor ETF Trust8260 00For
Advisors' Inner Circle Fund III2440 00For
E Trade Trust100 00For

Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan

Calculated outcomeCOMPENSATIONPassed (calculated)

99.0% Majority: yes · of votes cast

FOR 99.0%
FOR: 50,599,032AGAINST: 498,186
Details: description as filed, official tally, votes by 19 asset managers

Description as filed by funds: APPROVAL OF AN AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2022 EQUITY INCENTIVE PLAN.

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“4. Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan”): 50,599,032 for, 498,186 against, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 19 asset managers below reported 2,359,035 for.

FOR
FOR: 2,359,035
Largest asset managers voting on “APPROVAL OF AN AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2022 EQUITY INCENTIVE PLAN.” at MOONLAKE IMMUNOTHERAPEUTICS, 2025-2026
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price1,222,1730 00For
BlackRock286,4160 00For
Fidelity231,8400 00For
Jackson National111,7540 00For
Vanguard95,2330 00For
Invesco94,2340 00For
Delaware/Macquarie80,0000 00For
Victory Capital64,3170 00For
ALPS ETF Trust58,3950 00For
Advisor Managed Portfolios24,4190 00For
John Hancock22,5850 00For
ETFis Series Trust I17,5620 00For
Vident Advisory, LLC17,3610 00For
Equitable17,1510 00For
CLEARWATER INVESTMENT TRUST10,5150 00For
Blackstone Alternative Investment Funds4,0000 00For
Harbor ETF Trust8260 00For
Advisors' Inner Circle Fund III2440 00For
E Trade Trust100 00For

Advisory Vote on Executive Compensation

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 50,365,168AGAINST: 731,158

Prior year: 99.8% for (June 5, 2025 meeting) ▼ 1.2 pts

Details: description as filed, official tally, votes by 123 asset managers

Description as filed by funds: Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 50,365,168 for, 731,158 against, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 18 asset managers voting on “Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at MOONLAKE IMMUNOTHERAPEUTICS, 2025-2026
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price1,222,1730 00For
BlackRock286,4160 00For
Fidelity231,8400 00For
Jackson National111,7540 00For
Vanguard95,2330 00For
Invesco094,234 00Against
Delaware/Macquarie80,0000 00For
Victory Capital64,3170 00For
ALPS ETF Trust58,3950 00For
Advisor Managed Portfolios24,4190 00For
John Hancock22,5850 00For
ETFis Series Trust I17,5620 00For
Equitable17,1510 00For
CLEARWATER INVESTMENT TRUST10,5150 00For
Blackstone Alternative Investment Funds4,0000 00For
Harbor ETF Trust8260 00For
Advisors' Inner Circle Fund III2440 00For
E Trade Trust010 00Against

Fund voting reports, all 18 managers: 2,247,430 for, 94,244 against.

Institutional-manager reports: 109 asset managers voting on “Approval of, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at MOONLAKE IMMUNOTHERAPEUTICS, 2025-2026
Asset managerForAgainst AbstainWithheldVote
BVF INC/IL16,001,2840 00For
Deep Track Capital, LP6,408,8630 00For
Janus Henderson6,184,4660 00For
Cormorant Asset Management, LP3,111,3870 00For
Logos Global Management LP1,821,2620 00For
MPM BioImpact LLC1,811,0820 00For
T. Rowe Price1,594,7390 00For
Two Sigma1,029,4860 00For
GREAT POINT PARTNERS LLC1,000,0000 00For
Vivo Capital, LLC1,000,0000 00For
Citadel903,1500 00For
DE Shaw720,0830 00For
BALYASNY ASSET MANAGEMENT L.P.661,7700 00For
Point72653,0570 00For
BlackRock624,2868,921 00For
MARSHALL WACE, LLP415,9730 00For
Holocene Advisors, LP402,4290 00For
Candriam S.C.A.0340,426 00Against
Voleon Capital Management LP315,6840 00For
ADAR1 Capital Management, LLC276,2240 00For
Boxer Capital Management, LLC266,9270 00For
Renaissance215,7400 00For
HighVista Strategies LLC193,9550 00For
ACUTA CAPITAL PARTNERS, LLC192,3640 00For
Granahan Investment Management, LLC186,9070 00For

Institutional-manager reports, all 109 managers: 47,526,903 for, 629,001 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor

Calculated outcomeAUDIT-RELATEDPassed (calculated)

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 61,831,463AGAINST: 17,522

Prior year: 100.0% for (June 5, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 18 asset managers

Description as filed by funds: RATIFICATION, BY ORDINARY RESOLUTION, OF THE SELECTION OF BAKER TILLY US, LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026.

MOONLAKE IMMUNOTHERAPEUTICS’s own tally for this item (“2. Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor”): 61,831,463 for, 17,522 against, per its Form 8-K filed June 9, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 18 asset managers below reported 2,341,674 for.

FOR
FOR: 2,341,674
Largest asset managers voting on “RATIFICATION, BY ORDINARY RESOLUTION, OF THE SELECTION OF BAKER TILLY US, LLP AS THE COMPANY'S INDEPENDENT REG” at MOONLAKE IMMUNOTHERAPEUTICS, 2025-2026
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price1,222,1730 00For
BlackRock286,4160 00For
Fidelity231,8400 00For
Jackson National111,7540 00For
Vanguard95,2330 00For
Invesco94,2340 00For
Delaware/Macquarie80,0000 00For
Victory Capital64,3170 00For
ALPS ETF Trust58,3950 00For
Advisor Managed Portfolios24,4190 00For
John Hancock22,5850 00For
ETFis Series Trust I17,5620 00For
Equitable17,1510 00For
CLEARWATER INVESTMENT TRUST10,5150 00For
Blackstone Alternative Investment Funds4,0000 00For
Harbor ETF Trust8260 00For
Advisors' Inner Circle Fund III2440 00For
E Trade Trust100 00For

Largest MOONLAKE IMMUNOTHERAPEUTICS shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 73,615,396 shares outstanding at the time of that meeting.

Fund voting reports: top MOONLAKE IMMUNOTHERAPEUTICS shareholders by shares voted on “Approval of, on a non-binding, advisory basis, the compensation of the Company's named…”, 2025-2026
#Asset manager % of shares outstanding
1T. Rowe Price 1.66%
2BlackRock 0.39%
3Fidelity 0.31%
4Jackson National 0.15%
5Vanguard 0.13%
6Invesco 0.13%
7Delaware/Macquarie 0.11%
8Victory Capital 0.09%
9ALPS ETF Trust 0.08%
10Advisor Managed Portfolios 0.03%
Institutional-manager reports: top MOONLAKE IMMUNOTHERAPEUTICS shareholders by shares voted on “Approval of, on a non-binding, advisory basis, the compensation of the Company's named…”, 2025-2026
#Asset manager % of shares outstanding
1BVF INC/IL 21.74%
2Deep Track Capital, LP 8.71%
3Janus Henderson 8.40%
4Cormorant Asset Management, LP 4.23%
5Logos Global Management LP 2.47%
6MPM BioImpact LLC 2.46%
7T. Rowe Price 2.17%
8Two Sigma 1.40%
9GREAT POINT PARTNERS LLC 1.36%
10Vivo Capital, LLC 1.36%

Reported MOONLAKE IMMUNOTHERAPEUTICS holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

MOONLAKE IMMUNOTHERAPEUTICS holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BVF PARTNERS L P/IL16,001,284 21.74%Schedule 13D, filed June 29, 2026
Certain funds managed by BVF Partners L.P.16,001,284 21.74%Proxy statement (DEF 14A), proxy filed April 21, 2026
Deep Track Capital, LP7,999,025 10.87%Schedule 13G, filed August 14, 2026
Entities affiliated with Deep Track Capital, LP4,610,071 6.26%Proxy statement (DEF 14A), proxy filed April 21, 2026
Entities affiliated with Cormorant Asset Management, LP4,355,433 5.92%Proxy statement (DEF 14A), proxy filed April 21, 2026
Dr. Jorge Santos da Silva3,074,893 4.18%Proxy statement (DEF 14A), proxy filed April 21, 2026
Dr. Kristian Reich3,044,758 4.14%Proxy statement (DEF 14A), proxy filed April 21, 2026
D.E. Shaw2,390,661 3.25%Form 13F, quarter ended March 31, 2026
Citadel Advisors2,081,728 2.83%Form 13F, quarter ended March 31, 2026
Point721,368,518 1.86%Form 13F, quarter ended March 31, 2026

Percentages above are of 73,615,396 shares outstanding, as reported by MOONLAKE IMMUNOTHERAPEUTICS on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At MOONLAKE IMMUNOTHERAPEUTICS's shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 123 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 317 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval of, on a non-binding, advisory basis, the compensation of the Company's named… — FOR was 99% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: MOONLAKE IMMUNOTHERAPEUTICS's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MOONLAKE IMMUNOTHERAPEUTICS’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

MOONLAKE IMMUNOTHERAPEUTICS proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “MOONLAKE IMMUNOTHERAPEUTICS (MLTX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/moonlake-immunotherapeutics/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.